Judicious use of topical corticosteroids for their non-specific anti-inflammatory effect is central to the management of eczema, whatever its cause. Their effect is suppressive and if the cause of the eczema continues to operate over an indefinite period, topical therapy will have to be prolonged, bringing in its wake the now well-known hazards of such treatment.
Hydrocortisone
Hydrocortisone, 1% or even 0.5%, is the weakest, but may be quite adequate and effective in low-grade eczema. Its chief virtue is that it does not induce the serious local effects seen with its halogenated derivatives. It is appropriate, for instance, for chronic atopic eczema, pityriasis alba, or any facial eczema.
Low-potency Halogenated Corticosteroids
These are of low potency either because of the compounds chosen-example, Ultradil-or because of the concentration employed-example, Synandone, or Haelan. Many patients can be safely helped over long periods by these preparations, some of which can be sensibly and economically prescribed in large tubes (50g or 60g).
Standard Strength Compounds
Several standard strength compounds are available and (notwithstanding various claims to the contrary) the following are of roughly equal clinical effectiveness in eczema, in the concentrations at which they are presented: 0.1 % triamcinolone acetonide (Adcortyl); 0.025% fluocinolone acetonide (Synalar); 0.1% betamethasone valerate (Betnovate); and 0.025 % beclomethasone dipropionate (Propaderm) .
The prescriber will make his own choice (as will often the patient), perhaps partly influenced by the considerable variations in price, but more by the patients' tolerance of the base of the chosen preparation.
Two more recent products are claimed to have particularly virtuous bases (Metosyn and Topilar) but in my view they have not added a significant new dimension to therapy.
High-potency Compounds
These are Propaderm Forte (0.5%); Synalar Forte (0.2%). Both of these preparations are presented in 5-g tubes, and are intended to be reserved for particularly resistant and localized conditions. They are occasionally of value in small but intractable areas of nummular eczema.
It is not yet clear where the new preparation clobetasol propionate, 0.05% (Dermovate) should be placed. In terms of potency, it should probably be placed with the last category, but, in offering it in 25-g and 100-g tubes, the manufacturers would clearly prefer it to be top of the second (standard) division. At present, it is probably best reserved for the most stubborn eczemas (as the manufacturer indicates) and, unless diluted, should not lightly be re-prescribed over long periods. Creams should not often be diluted as their stability, sterility, and ability to release the active agent may all be compromised. Topilar cream may be diluted if the manufacturer's special base provided for this purpose is used (F.A.P.G. diluent).
The standard strength corticosteroid ointments (except Metosyn) may be safely diluted with soft white paraffin B.P. One-in-four or one-in-five dilutions allow adequate amounts of an effective ointment to be economically supplied, but the dilution can be reduced or even increased (example, to one-inten) as appropriate. The clinician should be guided by the principle of using the lowest strength of steroid adequate for its purpose.
INTRALESIONAL THERAPY
Direct injection of a steroid into a recalcitrant plaque of eczema may be useful if this manoeuvre is not overused. Adcortyl suspension (10 mg/ml) is usually given either by intradermal needle or (in the clinic) by Dermojet gun. The action may last for many weeks owing to the depot effect produced by the highly water-insoluble steroid in situ. It is not usual to employ these techniques unless topical therapy has failed.
PLACE OF POLYETHYLENE OCCLUSION
After steroid preparations have been applied to the skin, covering it with any material impermeable to water vapour (example, polyethylene) will enhance the penetration of the steroid through the epidermis by hydrating the stratum corneum and thus reducing the latter's barrier efficiency. Polyethylene gloves may be used for the hands and bags for the feet. This procedure potentiates the effects of the steroids, but the other effects of such hydration should be not forgotten. Firstly, the proliferation of the surface bacteria is promoted-so that if pathogenic staphylococci are present in the occluded area serious pyoderma may result. Secondly, enhancing the potency of the steroids implies a risk of correspondingly magnified side effects. Nevertheless, nocturnal occlusion may be very useful in noninfected intractable eczemas of the hands and feet, especially of the hyperkeratotic variety.
TOPICAL STEROID-ANTIBIOTIC COMBINATIONS
A "blunderbuss" approach to the topical treatment of eczema is rarely needed or rational. Infective retroauricular eczema in children (usually atopic), and the infective eczema not uncommonly seen about the toes in older boys-and more rarely on the hands in adults-are clear indications for steroidantibiotic combinations. They may also be needed in seborrhoeic eczema. In older women acute intertrigo is often wrongly regarded as a pure monilial infection, but it may have bacterial and eczematous elements and, if so, usually (1) When localized eczema is complicated by lymphangitis or cellulitis and tender regional lymphadenopathy.
Such infection may be assumed to be streptococcal and is usually seen with acute pompholyx eczema of the hands or an acute or chronic eczema of the feet. Less often it originates in hypostatic eczema associated with a gravitational ulcer. Potassium penicillin V is the drug of choice since S. pyogenes is always sensitive to it. If the patient is known to be allergic to penicillin, erthromycin is the best alternative.
In patients with recurring attacks of streptococcal cellulitisassociated, for instance, with a chronic endogenous eczema of the foot-long-term maintenance penicillin (potassium penicillin V, 250 mg, twice daily) may be indicated to prevent progressive lymphatic damage, increasing oedema, and reciprocal aggravation of the eczema itself.
Failure of acute lymphangitis to respond to adequate doses of penicillin may be puzzling and is generally attributable to mixed infection of the primary eczema with a penicillin-resistant Staph. aureus, whose penicillinase is gratuitously protecting the streptococcus: switching to flucloxacillin produces rapid resolution.
(2) When an eczema is complicated by painful folliculitis and "boils," which are making the patient "toxic." Such staphylococcal infection may sometimes be directly attributable to topical steroid therapy.
(3) In infected seborrhoeic eczema which is resistant to topical therapy.
(4) In acute infective "dermatitis" of the feet in older boys, usually seen about the toe clefts and dorsa of the feet near the bases of the great toes.
In all the above instances the sooner bacteriological culture and antibiotic sensitivity data are available the better-though the doctor should not wait for these before he starts treatment.
Apart from the instances just described, the role of microorganisms in eczema is controversial and here bacteriological information may only mislead.
ANTIHISTAMINES
As a specific remedy for the pruritus of eczema the antihistamines are disappointing. Nevertheless, in many patients they do reduce itching and are particularly valuable in atopic and nummular eczema; they may usefully be tried whenever the itching is severe and not easily controlled by topical treatment.
Compounds with a sedative action, such as promethazine and trimeprazine, are often the best but if necessary the doctor should be prepared to try others-for example, chlorphenramine maleate. (1) At the beginning of an acute attack of hand and foot pompholyx in a patient who has suffered previous fulminating attacks, associated with total disability as the extremities are "de-gloved": here treatment need last only a few weeks.
(2) In eczema which has evolved into generalized exfoliative dermatitis which is not settling spontaneously and is leading to potentially dangerous metabolic sequelae-for example, circulatory overload in an old person with heart disease.
(3) In the worst forms of intractable disabling endogenous eczema in adults as maintenance therapy. Patients with chronic eczema easily become steroid-dependent and maintenance treatment should not be started lightly.
(4) Rarely, for quick control of a severe contact eczema (especially on the face) where the cause has been identified and withdrawn; treatment is necessary for only a few days.
In every eczematous patient the likely benefits of steroid therapy have to be weighed against the hazards, whose extent must depend on the patient's overall medical condition.
Prednisolone is the drug of choice and the dose depends on the clinical state. In very acute contact eczema 40 mg daily would be an appropriate starting dose for two to three days, reduced steadily to zero subsequently over seven to ten days. In severe bullous pompholyx, a similar starting dose can be reduced quickly to 20 mg, then more slowly to zero over three to six weeks. In generalized exfoliative dermatitis 30-40 mg daily may have to be maintained for one to two weeks to allow metabolic faults to be corrected before the dose is judiciously reduced to the minimum effective maintenance level.
In other forms of chronic intractable eczema it is unwise to begin treatment with such high doses, lest patients experience a degree of control which cannot safely be maintained: 20 mg daily for two to four weeks is usually appropriate, the dose then being reduced by 2.5 mg and later 1.0 mg to the threshold level of control; often daily doses of 5.0-8.0 mg will be adequate. 
